N,N-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine → N,N-dimethyl-5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-7-morpholinothiazolo[5,4-d]pyrimidin-5-yl)pyrimidin-2-amine

Participants

Role	Name	HCID	Charge
Reactant	N,N-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine	HCID 16414215	—
Reactant	5-Chloro-2-((4-methylsulfonylpiperazin-1-yl)methyl)-7-morpholinothiazolo[5,4-d]pyrimidine	HCID 44541675	—
Product	N,N-dimethyl-5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-7-morpholinothiazolo[5,4-d]pyrimidin-5-yl)pyrimidin-2-amine	HCID 25254150	10.7%

Reaction Steps

5-Chloro-2-(4-methanesulfonyl-piperazin-1-ylmethyl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine (80 mg) was reacted with 55 mg of dimethyl-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrimidin-2-yl]-amine via General Procedure A. The product was purified by reverse phase HPLC to yield 10.3 mg of 110. MS (Q1) 520.2 (M)+.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US07893059B2
Source dataset	uspto-grants-2011_02
ORD ID	ord-76eefbf6b4a9406d8349610711efb659
Source note	uspto-grants-2011_02